-:: Directions ::-

> Home > Preclinical Studies > Clinical Program > QC Technology > Corporate Overview > Newsroom

»	Page 1
»	Page 2
»	Page 3

»	“Seeking FDA Approval for a Botanical Prescription Drug: Case Study of PHY906”
»	“PHY906: Enhancement of Cancer Chemotherapeutic Agents and Insights into Mechanism of Action”
»	“Developing PHY906 as a Broad- Spectrum Modulator of Chemotherapeutic Agents in Cancer Therapy”
»	“PHY906, a Chinese herbal formulation enhances the therapeutic effect of cancer chemotherapy in human colorectal and liver cancer”
»	“Scutellaria baicalensis Georgi, a commonly used herb in Chinese medicine, could facilitate oral absorption of drugs and overcome multidrug resistance in cancer caused by P-glycoprotein 170”
»	“Developing PHY906 as a modulator in cancer chemotherapy”
»	“Botanical Activity Relationship in Traditional Chinese Medicine: Studies of PHY906 as an Adjuvant Therapy with Cancer Chemotherapeutic Agents”
»	“A Chinese Medicine Formulation, PHY-906, Can Enhance The Therapeutic Index of CPT-11 and Other Anticancer Drugs Against Cancer in Mice”
»	“Using Modern Technology in Developing a Chinese Herbal Medicine”
»	“Prevention of CPT-11 Induced Toxicity by a Chinese Medicinal Formulation, PHY-906”

I I I

PhytoCeutica, Inc. 5 Science Park, Suite 13,New Haven, CT 06511, Phone: 203-777-3462, Fax: 203-777-3538

E-mail: info@phytoceutica.com

www.audinwebdesign.com